Shares of immunodiagnostics company Oncimmune Holdings (LON: ONC) are climbing after announcing it has signed an autoantibody profiling contract with Dana-Farber Cancer Institute in Boston, Massachusetts.Â
Dana Farber has been described as a world leader in adult and paediatric cancer treatment and research; it currently has more than 1,100 therapeutic and non-therapeutic clinical trials in progress.
The agreement will see Oncimmune use its biomarker discovery engine, SeroTag, to identify autoantibodies that can predict patient response used in Dana-Farber led studies or therapy using atezolizumab, nivolumab, pembrolizumab, durvalumab, and cisplatin-based chemotherapy.Â
SeroTag will also be used to identify autoantibodies that can predict immune-related adverse events in response treatment. The project is set to be completed by the end of this year.Â
Dr Adam Hill, CEO of Oncimmune, said: “We are delighted to be partnering with such a prestigious organisation as Dana-Farber on the use of multiple CPI assets in this important oncology trial and leveraging the power of our autoantibody biomarker profiling technology.
“As autoantibodies continue to be recognised as a key biomarker class that aid in the understanding of interactions between cancer and the immune system, the ImmunoINSIGHTS platform is becoming increasingly instrumental in studies for a wide range of cancer indications and therapy classes.”Â
Oncimmune's share price has gained 6.47% so far in Friday's session, sitting at 181p per share.
Should you invest in Oncimmune shares?
Oncimmune shares are traded on the London stock exchange's AIM market (the alternative investment market), which is the submarket specifically for smaller companies. AIM stocks are attractive to investors as they have tax advantages and smaller companies have the potential to benefit from rapid growth. But are Oncimmune shares the best buy? Our stock market analysts regularly review the market and share their picks for high growth companies